Baxter International’s stock took a hit after a mixed third quarter, missing analyst profit estimates. Sales rose 5% to $2.84 billion, but net income dropped by 14% to $355 million. Two segments saw growth, while medical products and therapies declined. Guidance for the full year fell short, with sales growth expected at 1-2% and adjusted net income below analyst estimates. The Motley Fool recommends 10 other stocks over Baxter International for potential high returns. Stock Advisor’s average return is 1,071%, outperforming the S&P 500 by 875%.

Read more at Nasdaq: Why Baxter International Stock Dived by Nearly 15% Today